Skip to main content

Table 1 Numbers of patients participating in the ATTAIN, ASSURE, ARRIVE, and ACTION studies who were taking one csDMARD in combination with abatacept or placebo

From: Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

  Number of patients  
ATTAIN ASSURE ARRIVE ACTION Total
ABA + MTX 175 535 490 1182 2382
PBO + MTX 89 243 332
ABA + HCQ 11 35 49 57 152
PBO + HCQ 2 33 35
ABA + SSZ 10 36 32 45 123
PBO + SSZ 4 10 14
ABA + AZA 4 10 30 15 59
PBO + AZA 1 9 10
ABA + LEF 17 62 65 253 397
PBO + LEF 7 29 36
  1. ABA abatacept, AZA azathioprine, csDMARD conventional synthetic disease-modifying antirheumatic drug, HCQ hydroxychloroquine, LEF leflunomide, MTX methotrexate, PBO placebo, SSZ sulfasalazine